头孢他啶联合阿米卡星对白血病化疗后粒细胞缺乏合并感染患者血清hs-CRP、PCT、IL-6水平及预后的影响

目的 探讨头孢他啶联合阿米卡星对白血病化疗后粒细胞缺乏合并感染患者血清高敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、降钙素原(PCT)水平及预后的影响。 方法 选取2013年3月—2015年4月宁波市鄞州人民医院收治的62例白血病化疗后发生粒细胞缺乏合并感染患者，通过随机数字表法分为2组。对照组单用头孢他啶治疗，研究组联合采用阿米卡星及头孢他啶，2组均持续治疗1周。比较2组临床疗效、血清hs-CRP、IL-6、PCT水平、不良反应发生率、12个月后生存率。 结果 研究组治疗有效率为83.87%(26/31)，明显高于对照组的61.29%(19/31)(P<0.05)。治疗后，2组hs-CRP、IL-6、PC水平均明显降低(均P<0.05)，且研究组血清hs-CRP、IL-6、PCT水平明显低于对照组(均P<0.05)。研究组不良反应发生率为12.90%(4/31)，对照组为9.67%(3/31)，2组比较差异无统计学意义(P>0.05)。研究组生存率为87.10%(27/31)，明显高于对照组的64.52%(20/31)(P<0.05)。 结论 阿米卡星联合头孢他啶可有效降低白血病化疗后粒细胞缺乏合并感染患者血清hs-CRP、PCT、IL-6水平，提高治疗效果及生存率，改善预后。 

Effects of ceftazidime combined amikacin on serum levels of hs-CRP,PCT,IL-6 and prognosis of patients with leukemia after leukemia chemotherapy

Objective To investigate the effects of ceftazidime combined amikacin on serum levels of hs-CRP,PCT,IL-6 and prognosis of patients with leukemia after leukemia chemotherapy. Methods Sixty-two patients with leukemia after leukemia chemotherapy in Ningbo Yinzhou people's hospital from March,2013 to April,2015 were selected and randomly divided into two groups.The control group was given ceftazidime,and research group was given amikacin combined ceftazidime.Both groups were treated for 1 week.The clinical efficacy,serum hs-CRP,IL-6 and PCT levels,adverse reactions incidence,survival rate after 12 months of two groups were compared. Results The effective rate of research group was 83.87%(26/31),which was significantly higher than that of control group61.29%(19/31)],P<0.05.After treatment,the serum hs-CRP,IL-6 and PCT levels of two groups were significantly reduced(P<0.05),and serum hs-CRP,IL-6 and PCT levels of research group were significantly lower than control group(P<0.05).The adverse reaction incidence of research group was 12.90%(4/31),and adverse reaction incidence of control group was 9.67%(3/31),there was no significant difference between two groups.The survival rate of research group was 87.10%(27/31),which was significantly higher than that of control group 64.52%(20/31),P<0.05. Conclusion Amikacin combined ceftazidime could effectively reduce serum hs-CRP,PCT and IL-6 levels of patients with leukemia after leukemia chemotherapy,enhance the therapeutic effect and survival rate,improve the prognosis.